First‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1: A case report

A 90‐year‐old female was admitted to our hospital with a history of a dry cough. Chest computed tomography (CT) scan showed a tumor shadow, and CT‐guided lung biopsy revealed squamous cell carcinoma harboring an EGFR mutation. In addition, programmed death‐ligand 1 (PD‐L1) was highly expressed with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamai, Kosuke, Tanahashi, Hiroki, Ueno, Sayaka, Konishi, Hanae, Matsumura, Mirai, Nomura, Akio, Nakamoto, Kanako, Isoyama, Shoko, Tanimoto, Takuya, Shoda, Hiroyasu, Ishikawa, Nobuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262880/
https://www.ncbi.nlm.nih.gov/pubmed/32291904
http://dx.doi.org/10.1111/1759-7714.13436
Descripción
Sumario:A 90‐year‐old female was admitted to our hospital with a history of a dry cough. Chest computed tomography (CT) scan showed a tumor shadow, and CT‐guided lung biopsy revealed squamous cell carcinoma harboring an EGFR mutation. In addition, programmed death‐ligand 1 (PD‐L1) was highly expressed with a tumor proportion score (TPS) of >75%. Pembrolizumab therapy in the first‐line setting was not effective, and the patient died at six months from the first visit. Squamous cell lung cancers (SCLCs) with both EGFR mutation and high expression of PD‐L1 are very rare.

Ejemplares similares